Home Biosimilar Antibodies Others Others Naxitamab (Anti-GD2)
For research use only. Not for use in humans.

Naxitamab (Anti-GD2)

Synonyms: GD2 ganglioside， Disialoganglioside GD2

Naxitamab (Anti-GD2) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers. MW: 145.5 KD.

Naxitamab (Anti-GD2)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Mechanism of Action

Description
Naxitamab (Anti-GD2) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers. MW: 145.5 KD.

Product Details

CAS No. 1879925-92-4
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06540963 RECRUITING Drug: Tipifarnib|Drug: Naxitamab Neuroblastoma Giselle Sholler 2024-12-06 PHASE2
NCT05489887 RECRUITING Drug: Naxitamab Neuroblastoma Giselle Sholler 2022-09-14 PHASE2
NCT07011654 RECRUITING Drug: Sacituzumab govitecan|Drug: Naxitamab Metastatic Triple-Negative Breast Cancer M.D. Anderson Cancer Center 2025-09-19 PHASE1; PHASE2
NCT07537400 NOT_YET_RECRUITING Drug: Naxitamab High-Risk Neuroblastoma Shaare Zedek Medical Center 2026-05 PHASE2
NCT05298995 RECRUITING Brain Tumor, Pediatric; Medulloblastoma, Childhood; Embryonal Tumor; High Grade Glioma; Diffuse Midline Glioma; Diffuse Intrinsic Pontine Glioma; Brain Tumor Adult Bambino Gesù Hospital and Research Institute 2023-11-09 PHASE1
NCT06026657 RECRUITING Drug: Gemcitabine Anatomic Stage IV Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma Margaret Gatti-Mays 2024-04-02 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.